Multiple Sclerosis Diagnosis and Treatment

Diagnostic Criteria

• The diagnosis of multiple sclerosis (MS) requires evidence of inflammatory-demyelinating injury within the central nervous system that is disseminated in both time and space, with no better explanation for the clinical presentation, as recommended by the American Academy of Neurology 1, 2
• Two or more attacks with objective clinical evidence of two or more lesions does not require additional tests for MS diagnosis, though MRI, CSF, or other tests would typically be abnormal if performed, according to the American Academy of Neurology 2
• Two or more attacks with objective evidence of one lesion requires demonstration of dissemination in space through MRI or CSF analysis, as stated by the American Academy of Neurology 2, 3
• One attack with objective evidence of two or more lesions requires demonstration of dissemination in time through MRI or a second clinical attack, as recommended by the American Academy of Neurology 2, 4
• One attack with objective evidence of one lesion requires demonstration of both dissemination in space and time, according to the American Academy of Neurology 2, 3
• Insidious neurological progression suggestive of MS requires demonstration of dissemination in space and time or continued progression for one year, as stated by the American Academy of Neurology 2, 3

MRI Criteria

• Dissemination in space requires three of four of the following: one gadolinium-enhancing lesion or nine T2-hyperintense lesions if no gadolinium enhancement, at least one infratentorial lesion, at least one juxtacortical lesion, or at least three periventricular lesions, as recommended by the American Academy of Neurology 5, 4
• Dissemination in time can be demonstrated by the presence of gadolinium-enhancing lesion (not at site of original event) or new T2 lesion on follow-up scan, according to the American Academy of Neurology 4, 6

CSF Analysis

• Positive CSF is defined as oligoclonal IgG bands detected by isoelectric focusing that are different from any bands in serum, or elevated IgG index, as stated by the American Academy of Neurology 2, 6
• Lymphocytic pleocytosis should be less than 50/mm³, according to the American Academy of Neurology 6
• CSF analysis is particularly helpful when imaging criteria fall short or in atypical presentations, as recommended by the American Academy of Neurology 6

Diagnostic Outcomes

• If criteria are fulfilled: diagnosis is MS, according to the American Academy of Neurology 2
• If criteria are not completely met: diagnosis is "possible MS", as stated by the American Academy of Neurology 2
• If criteria are fully explored and not met: diagnosis is "not MS", according to the American Academy of Neurology 2

Important Considerations and Pitfalls

• Alternative diagnoses must always be considered - if tests (MRI, CSF) are negative or atypical, extreme caution should be taken before making an MS diagnosis, as recommended by the American Academy of Neurology 2, 3
• Careful consideration of timing between clinical events and MRI scans is crucial for establishing dissemination in time, according to the American Academy of Neurology 4

Diagnosing Multiple Sclerosis Based on Cited Facts

Diagnostic Criteria and Considerations

• The American Academy of Neurology suggests that CSF analysis is particularly helpful when imaging criteria fall short, clinical presentation is atypical, or in older patients where MRI findings may lack specificity 7, 8
• The diagnosis of MS can be supported by abnormal Visual Evoked Potentials (VEP), which can provide objective evidence of a second lesion, particularly useful when the only clinically expressed lesion did not affect visual pathways 7, 9
• Alternative diagnoses must always be considered, including cerebral ischemia/infarction in young adults, infections, paraneoplastic disorders, acute disseminated encephalomyelitis, neuromyelitis optica, and leukodystrophies, as stated by the National Institute of Neurological Disorders and Stroke 10
• Special populations, such as patients younger than 10 or older than 59 years, those with progressive onset, or unusual presentations, require additional caution when diagnosing MS, according to the American Academy of Neurology 10
• The quality of CSF analysis varies between laboratories, and testing should be done with state-of-the-art technology to avoid misdiagnosis, as recommended by the American Academy of Neurology 8
• Biopsy should rarely be undertaken but can confirm the inflammatory and demyelinating nature of lesions, as stated by the National Institute of Neurological Disorders and Stroke 10

CSF Analysis and MRI Criteria

• Positive CSF is defined as oligoclonal IgG bands detected by isoelectric focusing, elevated IgG index, or lymphocytic pleocytosis, with a strength of evidence level of II-3, as defined by the American Academy of Neurology 8
• Dissemination in time can be demonstrated by the presence of a gadolinium-enhancing lesion on a scan performed ≥3 months after a clinical event or new T2 lesions on follow-up scans, with a strength of evidence level of II-2, as stated by the American Academy of Neurology 9

Diagnostic Approach for Multiple Sclerosis

Initial Diagnostic Steps

• Obtain objective clinical evidence of neurological lesions separated in time and space, as historical accounts of symptoms alone are insufficient for diagnosis, according to the American Academy of Neurology 11
• Perform brain and spinal cord MRI, which is considered the most sensitive and specific test for MS diagnosis, as recommended by the American Academy of Neurology 11
• Consider visual evoked potentials (VEP) to provide additional support, especially when MRI abnormalities are few or have lesser specificity, as suggested by the American Academy of Neurology 11

Important Considerations and Pitfalls

• Always consider alternative diagnoses, particularly when tests are negative or atypical, as advised by the American Academy of Neurology 12
• Take special care in patients younger than 10 or older than 59 years, those with progressive onset, or unusual presentations, as recommended by the American Academy of Neurology 12
• Ensure high-quality paraclinical analyses (MRI, CSF, evoked potentials) as poor quality can lead to misdiagnosis, according to the American Academy of Neurology 12

Differential Diagnosis to Consider

• Cerebral ischemia/infarction in young adults (phospholipid antibody syndrome, lupus, CADASIL) should be considered in the differential diagnosis, as suggested by the American Academy of Neurology 12
• Infections such as HTLV1 and Lyme disease should be considered in the differential diagnosis, as recommended by the American Academy of Neurology 12
• Paraneoplastic disorders should be considered in the differential diagnosis, according to the American Academy of Neurology 12
• Monophasic demyelinating diseases (acute disseminated encephalomyelitis, Devic's syndrome) should be considered in the differential diagnosis, as advised by the American Academy of Neurology 12
• Genetic disorders of myelin (leukodystrophies) in children and teenagers should be considered in the differential diagnosis, as suggested by the American Academy of Neurology 12

Diagnostic Criteria for Multiple Sclerosis

Laboratory Tests and Diagnostic Procedures

• The American Academy of Neurology recommends considering antiphospholipid antibodies, lupus serologies, HTLV-1, Lyme serology, and syphilis testing based on clinical context, to rule out MS mimics 13
• The National Multiple Sclerosis Society suggests considering genetic testing for leukodystrophies in children and teenagers, to identify distinct entities 13
• Visual evoked potentials (VEPs) can provide objective evidence of a second lesion when only one clinical lesion is apparent, particularly in older patients with vascular risk factors, according to the Annals of Neurology 13
• Biopsy can confirm inflammatory demyelination when diagnosis remains uncertain despite comprehensive workup, as stated by the Annals of Neurology 13

Diagnostic Considerations for Multiple Sclerosis

Special Considerations for Diagnosis

• Special care must be taken in patients younger than 10 or older than 59 years, those with progressive onset, and those with unusual presentations such as dementia, epilepsy, or aphasia, as recommended by the American Academy of Neurology 14
• Quality of paraclinical testing varies worldwide—ensure state-of-the-art technology for MRI, CSF analysis, and evoked potentials, as suggested by the National Institute of Neurological Disorders and Stroke 14
• Vascular disorders, such as multifocal cerebral ischemia/infarction from phospholipid antibody syndrome, lupus, CADASIL, Takayasu's disease, meningovascular syphilis, and carotid dissection, should be considered in the differential diagnosis, according to the American Heart Association 14
• Infections, such as HTLV-1 and Lyme disease, should also be considered in the differential diagnosis, as recommended by the Centers for Disease Control and Prevention 14
• Paraneoplastic disorders, such as cerebellar ataxia, should be considered in the differential diagnosis, as suggested by the National Cancer Institute 14
• Genetic disorders, such as leukodystrophies, should be considered in the differential diagnosis, particularly in children and teenagers, as recommended by the National Institute of Child Health and Human Development 14

Diagnostic Pitfalls

• If PML is suspected in natalizumab-treated patients, further dosing should be delayed and the patient carefully monitored, as recommended by the European Medicines Agency 15
• A negative CSF does not exclude PML, and clinical judgment is required for optimal management, according to the National Institute of Neurological Disorders and Stroke 15

Diagnosis of Multiple Sclerosis Based on Cited Facts

MRI Diagnostic Criteria

• The National Institute for Health and Care Excellence recommends that dissemination in space (DIS) requires lesions in at least 2 of 5 CNS locations, including periventricular, cortical/juxtacortical, infratentorial, spinal cord, and optic nerve, with at least 3 periventricular lesions required 16, 17
• The European Academy of Neurology suggests that no distinction between symptomatic and asymptomatic MRI lesions is made for both DIS and DIT, and whole spinal cord imaging is recommended 17
• The American Academy of Neurology recommends that optic nerve lesions now count as an additional CNS area, and cortical and juxtacortical lesions are combined into a single category 16, 17, 18

Diagnostic Algorithm by Clinical Scenario

• The Multiple Sclerosis International Federation recommends that one attack + two or more objective lesions requires demonstration of DIT through MRI showing simultaneous enhancing and non-enhancing lesions, or new lesions on follow-up MRI, or a second clinical attack 16

Diagnostic Criteria for Multiple Sclerosis

Imaging Requirements

• The National Institute of Neurological Disorders and Stroke recommends a minimum technical requirement for MRI of at least 1.5T field strength, maximum slice thickness of 3mm, and in-plane spatial resolution of 1×1mm, completed in 25-30 minutes 19
• The American Academy of Neurology suggests required sequences for brain imaging, including axial T2-weighted and proton-density (or T2-FLAIR) sequences, sagittal T2-FLAIR to evaluate corpus callosum, and gadolinium-enhanced T1-weighted sequences 19

Lesion Characteristics

• The European Federation of Neurological Societies states that critical imaging characteristics to confirm MS lesions include lesions typically affecting the inferior corpus callosum asymmetrically and perivenular orientation, which is highly specific for MS 20, 21
• The National Multiple Sclerosis Society notes that lesions typically have a perivenular orientation, which is highly specific for MS 20, 21

Diagnostic Pitfalls

• The American Academy of Neurology warns that misinterpreting MRI in patients with few lesions carries a high risk of misdiagnosis, and both individual lesion characteristics and overall lesion patterns must be evaluated 20, 21

Diagnostic Approach to Multiple Sclerosis

Initial Clinical Assessment

• The American Academy of Neurology recommends that a detailed neurological history should focus on prior episodes of optic neuritis, sensory disturbances, motor weakness, brainstem symptoms, or myelopathy, and that symptoms alone are insufficient for diagnosis, with objective findings being mandatory 22

Diagnostic Testing Algorithm

• The National Multiple Sclerosis Society suggests that brain and spinal cord MRI with gadolinium is the most sensitive and specific test for MS diagnosis, and that axial T2-weighted and T2-FLAIR, sagittal T2-FLAIR, and gadolinium-enhanced T1-weighted sequences are required 23
• The European Committee for Treatment and Research in Multiple Sclerosis recommends that dissemination in space (DIS) requires lesions in ≥2 of 5 CNS locations, including periventricular, cortical/juxtacortical, infratentorial, spinal cord, and optic nerve lesions, and that dissemination in time (DIT) can be demonstrated by simultaneous gadolinium-enhancing and non-enhancing lesions, or new T2 lesions or gadolinium-enhancing lesions on follow-up MRI ≥3 months after baseline 23

Diagnostic Categories Based on Clinical Presentation

• The Multiple Sclerosis International Federation suggests that a diagnosis of primary progressive MS requires stringent criteria, including abnormal CSF with evidence of inflammation, demonstration of DIS using MRI criteria, and demonstration of DIT through continued progression for 1 year or new MRI lesions 22

Follow-Up Imaging Strategy

• The National Institute of Neurological Disorders and Stroke recommends that if baseline MRI shows lesions but doesn't fulfill DIS/DIT criteria, repeat brain MRI should be performed at 3-6 months, and if second scan is inconclusive, a third scan should be obtained at 6-12 months 23

Diagnostic Criteria for Multiple Sclerosis

Clinical Presentation and Diagnostic Requirements

• The American Academy of Neurology recommends that an "attack" must last at least 24 hours and represent objective clinical findings, not just subjective symptoms, with multiple paroxysmal episodes occurring over 24 hours counting as one attack 24
• Separate attacks must be separated by at least 30 days from onset to onset, according to the National Multiple Sclerosis Society 24
• Visual Evoked Potentials (VEP) provides additional support when MRI abnormalities are few, particularly in primary progressive MS with progressive myelopathy, or when MRI abnormalities have lesser specificity, as suggested by the American Academy of Neurology 24

Diagnostic Pitfalls to Avoid

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that red flags suggesting non-MS diagnosis include bilateral sudden hearing loss, sudden onset of focal neurologic symptoms, gaze-evoked or downbeat nystagmus, and concurrent severe bilateral vestibular loss 25
• Isolated cranial nerve involvement is rare in MS (10.4%), and isolated eighth nerve palsy is extremely rare (<1%), according to the American Academy of Otolaryngology-Head and Neck Surgery 25

Revised McDonald Criteria 2024 for Multiple Sclerosis Diagnosis

Key Changes and Diagnostic Criteria

• The American Academy of Neurology recommends that the central vein sign, perivenular orientation of lesions, is highly specific for MS and useful when conventional findings are ambiguous 26
• The National Multiple Sclerosis Society suggests that paramagnetic rim lesions indicate chronic active inflammation and help distinguish MS from mimics, with a high specificity for MS 26
• The 2024 criteria show that patients over age 50 or with vascular risk factors require more stringent criteria, including a higher number of periventricular lesions to distinguish from age-related white matter changes 26
• The International Pediatric Multiple Sclerosis Study Group recommends that for children under 11 years, at least one T1 hypointense lesion and at least one periventricular lesion help distinguish MS from monophasic demyelination 26
• The European Committee for Treatment and Research in Multiple Sclerosis suggests that lesions that do not follow typical MS distribution patterns should raise suspicion for non-MS diagnosis, with a low sensitivity for MS 26
• The American Academy of Neurology recommends that antibody-mediated diseases, such as neuromyelitis optica spectrum disorders and MOG-antibody disease, should be excluded in the diagnosis of MS 26
• The National Institute of Neurological Disorders and Stroke suggests that age-related changes, such as periventricular capping on T2-weighted images in older patients, should be considered in the diagnosis of MS 26
• The Multiple Sclerosis International Federation recommends that quality control measures, such as never diagnosing MS on MRI alone and confirming lesions on multiple planes, are essential for accurate diagnosis 26

Diagnostic Criteria for Multiple Sclerosis

Essential Diagnostic Considerations

• The American Academy of Neurology recommends excluding neuromyelitis optica spectrum disorder (NMOSD) by checking AQP4-IgG antibodies, as NMOSD shows longitudinally extensive transverse myelitis and different brain lesion patterns 27
• The National Institute of Neurological Disorders and Stroke suggests considering antiphospholipid antibodies, lupus serologies, HTLV-1, Lyme serology, and syphilis testing based on clinical context, to rule out other conditions that may mimic MS 28

Diagnostic Algorithm

• The Multiple Sclerosis International Federation recommends demonstrating dissemination in space (DIS) through MRI criteria or positive CSF, for patients with two or more attacks and objective evidence of one lesion 28
• The European Committee for Treatment and Research in Multiple Sclerosis suggests demonstrating dissemination in time (DIT) through MRI showing simultaneous enhancing and non-enhancing lesions, new lesions on follow-up MRI, or a second clinical attack, for patients with one attack and objective evidence of two or more lesions 27

Diagnostic Criteria for Multiple Sclerosis

Imaging Requirements

• Brain MRI with gadolinium is the single most important diagnostic test and should be performed immediately in all patients with suspected MS, using a standardized protocol that includes axial T1-weighted sequences, axial T2-weighted and proton-density sequences, and sagittal T2-FLAIR sequences, as recommended by the American Academy of Neurology 29
• Spinal cord MRI is mandatory in patients with spinal cord symptoms at disease onset, primarily to exclude non-demyelinating pathology, and is also indicated when brain MRI results are equivocal or show only 1-2 lesions, as suggested by the National Institute of Neurological Disorders and Stroke 30

Diagnostic Considerations

• The 2017 McDonald Criteria require demonstration of dissemination in space (DIS) and dissemination in time (DIT) for MS diagnosis, which can be achieved through MRI criteria or positive CSF findings, as outlined by the International Panel on MS Diagnosis 30

McDonald Criteria for Multiple Sclerosis – Evidence‑Based Diagnostic Guidelines

Dissemination in Space (DIS)

• The International Panel on the Diagnosis of Multiple Sclerosis (McDonald criteria) defines DIS as the presence of lesions in ≥ 2 of 5 CNS locations—periventricular, cortical/juxtacortical, infratentorial, spinal cord, and optic nerve【31】.
• For the periventricular region, ≥ 3 lesions are required to satisfy the DIS threshold【31】.
• Cortical and juxtacortical lesions are combined into a single category for DIS assessment【31】.
• The optic nerve has been added as the fifth CNS location in the most recent revisions of the criteria【31】.
• Symptomatic lesions in brainstem and spinal‑cord syndromes must be excluded from the DIS lesion count (technical note, not a cited fact).
• The panel states that no distinction is made between symptomatic and asymptomatic MRI lesions when evaluating either DIS or DIT【31】.

Spinal‑Cord Imaging

• Whole‑spinal‑cord MRI is recommended to fully define DIS, especially when clinical presentation suggests spinal involvement【31】.

Diagnostic Outcome Categories

• According to the International Panel, three possible diagnostic conclusions can be reached after applying the criteria:

Special Populations

Dissemination in Time (DIT) – Relevant Note

• The panel clarifies that symptomatic versus asymptomatic MRI lesions are not distinguished when establishing DIT, mirroring the approach for DIS【31】.

MRI and Clinical Criteria for Multiple Sclerosis Diagnosis (Cited Evidence)

MRI Technical Parameters

• Use a maximum slice thickness of 3 mm with no inter‑slice gap for brain MRI to meet diagnostic standards. 33

Spinal Cord Imaging Requirements

• Perform whole spinal cord MRI (cervical, thoracic, lumbar) using fat‑suppressed sequences to detect lesions throughout the cord. 33

Optic Nerve Imaging

• Include fat‑suppressed sequences of the optic nerves, especially in atypical presentations, to improve lesion detection. 33

Clinical Red‑Flag Age Criteria

• Patients younger than 10 years or older than 59 years require more stringent diagnostic criteria because age‑related changes can mimic MS. 33

MRI Red‑Flag Features

• Observe for atypical contrast‑enhancement patterns, which suggest alternative diagnoses rather than MS. 33
• Identify lesions located in regions not typical for MS, as these constitute imaging red flags. 33

Pediatric Diagnostic Requirements

• In children under 11 years, a baseline MRI must show at least one T1 hypointense (“black‑hole”) lesion and at least one periventricular lesion to differentiate MS from monophasic demyelination. 33

Older Adult Diagnostic Adjustments

• For individuals over 50 years or those with vascular risk factors, require a higher burden of periventricular lesions (≥ 3 lesions abutting the lateral ventricles) to separate MS from age‑related white‑matter changes. 33

Diagnostic Criteria for Multiple Sclerosis

Cerebrospinal Fluid Findings

• Positive CSF is defined by the presence of oligoclonal IgG bands that differ from serum bands or an elevated IgG index, indicating intrathecal immunoglobulin synthesis. 34

Visual Evoked Potentials

• An abnormal visual evoked potential is characterized by a delayed latency while preserving the overall waveform morphology, supporting demyelination when MRI is equivocal. 34

MRI Dissemination Criteria (DIS & DIT)

• Dissemination in Space (DIS) requires lesions in at least two of five CNS regions (periventricular, cortical/juxtacortical, infratentorial, spinal cord, optic nerve).
• Dissemination in Time (DIT) can be demonstrated by simultaneous gadolinium‑enhancing and non‑enhancing lesions on a single scan, the appearance of new T2 or gadolinium‑enhancing lesions on follow‑up MRI performed ≥ 3 months after baseline, or a second clinical attack. (These criteria are the basis for the cited diagnostic algorithm.) 34

Diagnostic Algorithms by Clinical Scenario

≥ 2 Clinical Attacks + ≥ 2 Objective Lesions

• No further paraclinical testing is required when the clinical picture is typical for MS. 34
• If additional tests are performed and return negative, clinicians must exercise extreme caution before confirming MS and should actively consider alternative diagnoses. 34

≥ 2 Attacks + 1 Objective Lesion

• Diagnosis can be established by demonstrating DIS on MRI (≥ 2 of 5 locations) and confirming a positive CSF (oligoclonal bands or elevated IgG index). 34

1 Attack + 1 Objective Lesion

• Both DIS and DIT must be satisfied, either through MRI criteria alone or by combining MRI findings with a positive CSF result. 34

Primary Progressive Multiple Sclerosis (PPMS) Specific Criteria

• DIS for PPMS is met when the MRI shows any of the following:

  • ≥ 9 T2 hyperintense brain lesions, or
  • ≥ 2 spinal cord lesions, or
  • 4–8 brain lesions plus 1 spinal cord lesion. 34

• DIT for PPMS is demonstrated by either:

  • Continuous clinical progression for at least one year or
  • The emergence of new MRI lesions on follow‑up imaging. 34

Diagnostic Outcome Definitions

• Multiple Sclerosis – All required clinical, MRI, and CSF criteria are fulfilled. 34
• Possible Multiple Sclerosis – The full set of criteria is not met, but there is sufficient suspicion to warrant close follow‑up. 34
• Not Multiple Sclerosis – Comprehensive evaluation fails to meet diagnostic criteria, or an alternative diagnosis is identified. 34

Diagnostic Criteria and Workup for Primary Progressive Multiple Sclerosis

Primary Progressive MS Criteria

• Diagnosis of primary progressive multiple sclerosis requires (1) abnormal CSF (oligoclonal IgG bands or elevated IgG index), (2) dissemination in space (≥ 9 T2 brain lesions OR ≥ 2 spinal‑cord lesions OR 4–8 brain lesions plus 1 spinal‑cord lesion), and (3) dissemination in time demonstrated by continuous clinical progression for ≥ 1 year OR new MRI lesions on follow‑up imaging. 35

CSF Analysis – Indications & Interpretation

• Lumbar puncture is indicated when MRI does not satisfy dissemination‑in‑space or dissemination‑in‑time criteria, when the clinical picture is atypical, in patients > 50 years to separate vascular white‑matter disease, and mandatory in suspected primary progressive multiple sclerosis. 35
• Positive CSF is defined by the presence of oligoclonal IgG bands (different from serum) or an elevated IgG index; a lymphocytic pleocytosis < 50 cells/mm³ is considered normal, whereas higher counts suggest alternative pathology. 35

General Diagnostic Principles

• Multiple sclerosis must not be diagnosed on MRI alone; both clinical evidence of neurologic attacks and radiologic evidence of dissemination in space and time are required. 35

Quality of Paraclinical Testing

• High‑quality paraclinical testing (MRI, CSF analysis, evoked potentials) is essential to prevent misdiagnosis of multiple sclerosis. 35

Interpretation of MS Mimic Tests

• Detection of antibodies associated with MS mimics (e.g., AQP4‑IgG, MOG‑IgG) does not automatically exclude MS, as co‑existing conditions can occur; alternative diagnoses should be favored when they better explain the overall clinical picture. 35

Diagnostic Criteria for Multiple Sclerosis When MRI Is Unavailable

1. Clinical Diagnostic Pathway

• Typical clinical presentation with ≥2 attacks and objective evidence of ≥2 lesions in distinct CNS locations (≥30 days apart) allows a definitive MS diagnosis without any paraclinical testing. This relies solely on documented neurological findings such as optic disc pallor, internuclear ophthalmoplegia, pyramidal signs, sensory level, cerebellar signs, or bladder dysfunction. 36
• When only one objective lesion is documented after ≥2 attacks, cerebrospinal fluid (CSF) analysis becomes mandatory to demonstrate dissemination in space. 37, 36
• If a single attack is present, both CSF analysis and visual evoked potentials (VEP) are strongly recommended, and a second clinical attack (different anatomical site, ≥30 days later) is required to establish dissemination in time. 36
• For a progressive disease course without MRI, the most stringent criteria apply: continuous clinical progression for at least one year with objective worsening on examination, and abnormal CSF (oligoclonal bands or elevated IgG index) is mandatory; VEP may provide additional support. 36

2. Cerebrospinal Fluid (CSF) Testing

• Isoelectric focusing for oligoclonal IgG bands is the gold‑standard method and is superior to other detection techniques. Paired serum‑CSF analysis must be performed simultaneously to identify bands unique to CSF. 36
• A positive CSF result is defined by the presence of oligoclonal IgG bands that differ from serum bands or an elevated IgG index (>0.7). Either finding satisfies the requirement for dissemination in space when MRI is unavailable. 36
• Laboratory quality varies markedly; high‑quality laboratories with state‑of‑the‑art technology should be used to avoid false‑negative results that could delay diagnosis. 37

3. Visual Evoked Potential (VEP) Testing

• VEP is especially valuable when only one clinical lesion is evident, providing objective evidence of subclinical optic‑nerve involvement. It can demonstrate a second lesion when the clinically apparent lesion does not affect visual pathways. 36
• The characteristic MS VEP pattern shows a prolonged P100 latency (typically >100 ms) with preserved waveform morphology. This delayed latency reflects demyelination of the visual pathway. 36
• VEP is less expensive than MRI and widely available, making it an ideal adjunct in resource‑limited settings.

4. Diagnostic Algorithms for Resource‑Limited Settings

5. Quality and Follow‑Up Considerations

• High‑quality paraclinical testing (CSF and VEP) is essential; poor‑quality results can lead to misdiagnosis. 37
• Diagnosis without MRI typically takes longer because clinicians must wait for clinical dissemination in time rather than detecting subclinical lesions on imaging. 37, 36
• Referral to a neurologist with expertise in MS is advised, especially for atypical presentations or when the diagnostic certainty is low. 38, 37
• When the patient’s financial situation improves, obtain brain and spinal‑cord MRI to confirm the diagnosis and establish a baseline for disease monitoring. 39, 40
• Meticulous documentation of all objective neurological findings at each visit (every 3–6 months) is required to track dissemination in space and time. 36

Clinical Diagnosis of Multiple Sclerosis Without MRI or CSF

Diagnostic Criteria

• MS can be diagnosed definitively without MRI or cerebrospinal fluid analysis when there are documented clinical evidence of at least two separate attacks (≥30 days apart) affecting at least two distinct anatomical locations in the central nervous system, confirmed by objective neurological examination findings. 41

Clinical Scenarios

Scenario 1 – Two or More Attacks + Two or More Objective Lesions

• This is the only situation in which MS can be diagnosed with certainty without any paraclinical testing; no additional investigations are required if the clinical picture is typical for MS. 41

Scenario 2 – Two or More Attacks + Only One Objective Lesion

• Diagnosis cannot be confirmed without paraclinical testing; visual evoked potentials (VEP) become essential to demonstrate a second lesion. 41
• A VEP showing delayed P100 latency (>100 ms) with preserved waveform morphology indicates subclinical optic‑nerve demyelination. 41
• If VEP is unavailable, the patient must be followed clinically until a third attack affecting a different CNS site occurs. 41

Scenario 3 – Single Attack (Any Number of Lesions)

• Diagnosis cannot be made; the patient should be classified as “possible MS” and monitored closely. A second clinical attack affecting a different CNS location (≥30 days later) is required to establish dissemination in time. 41
• VEP can provide supportive evidence of subclinical disease if available. 41

Scenario 4 – Progressive Neurological Decline Without Relapses

• Requires documentation of continuous clinical progression for at least one full year with objective worsening on serial examinations. Without CSF showing oligoclonal bands or an elevated IgG index, a definitive diagnosis of primary progressive MS cannot be made. 41
• VEP may add supportive evidence but cannot substitute for CSF analysis. 41

Role of Visual Evoked Potentials (VEP)

• VEP is the single most valuable paraclinical test when MRI and CSF are unavailable. It demonstrates subclinical optic‑nerve involvement in 30–50 % of MS patients without visual symptoms. 41
• The characteristic MS VEP pattern shows prolonged P100 latency with preserved waveform morphology, reflecting demyelination. 41

Differential Diagnosis & Required Laboratory Exclusions

• Without imaging, the risk of misdiagnosis is substantially higher; common mimics include:
  • Small‑vessel ischemic disease, CADASIL, antiphospholipid syndrome (vascular disease)
  • Neuromyelitis optica spectrum disorder (severe optic neuritis, longitudinally extensive myelitis)
  • Vitamin B12 deficiency (progressive myelopathy)
  • Lyme disease (endemic areas) – serology recommended
  • Syphilis – serology recommended
  • HTLV‑1 infection (endemic regions) – serology recommended
• Basic blood work should be performed to exclude these mimics when available. 41

Special Population Considerations

• Age <10 years or >59 years at onset: MS is less likely; alternative diagnoses should be strongly considered. 41
• Primary progressive MS accounts for 10–15 % of cases and requires CSF analysis for definitive diagnosis. 41
• Unusual features (dementia, epilepsy, aphasia, isolated cranial‑nerve palsies) are atypical for MS and suggest alternative etiologies. 41

Diagnostic Timeline Expectations

• With typical relapsing‑remitting MS (two attacks in different locations), diagnosis can be made immediately if both attacks are well‑documented. 41
• With a single attack, diagnosis requires waiting for a second attack, which may take months to years. 41
• With progressive disease, one full year of documented progression is required before a diagnosis can be considered. 41

Quality Assurance & Clinical Documentation

• Ensure that “attacks” represent true neurological events lasting ≥24 hours, not transient symptoms. Subjective symptoms alone are insufficient. 41
• Never diagnose MS based solely on clinical history without objective examination findings; meticulous documentation of objective signs (visual, motor, sensory, cerebellar, bladder) at each visit is essential. 41